This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
SpePharm enters into royalty agreement with Paul Capital
21 Aug 2014
Cancer and critical care company SpePharm Holdings BV has signed a €10mm ($14.75mm) revenue interest acquisition financing with Paul Capital Healthcare to fund SpePharm's recent purchase of European rights to Procter & Gamble's hyperthermia treatment Dantrium. Paul Capital also participated in a simultaneously announced €16mm equity financing for SpePharm, along with other investors.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?